<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">federalizm</journal-id><journal-title-group><journal-title xml:lang="ru">Федерализм</journal-title><trans-title-group xml:lang="en"><trans-title>Federalism</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2073-1051</issn><publisher><publisher-name>Plekhanov Russian University of Economics</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21686/2073-1051-2023-3-108-136</article-id><article-id custom-type="elpub" pub-id-type="custom">federalizm-805</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ЗАРУБЕЖНЫЙ ОПЫТ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>OVERSEAS EXPERIENCE</subject></subj-group></article-categories><title-group><article-title>Фармацевтическое государственное регулирование и экспорт лекарственных средств: зарубежный опыт</article-title><trans-title-group xml:lang="en"><trans-title>Drug Regulation in Top Exporters of Pharmaceutical Products</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Аладышева</surname><given-names>Ж. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Aladysheva</surname><given-names>Z. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Аладышева Жанна Игоревна, кандидат медицинских наук, доцент, доцент кафедры промышленной фармации</p><p>ул. Трубецкая, д. 8, стр. 2, г. Москва, 119048</p></bio><bio xml:lang="en"><p>Aladysheva Zhanna A., Cand. Sc. (Med), Associate Professor</p><p> 8, Building 2, Trubetskaya Str., Moscow, 119048</p></bio><email xlink:type="simple">zhaladysheva@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Береговых</surname><given-names>В. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Beregovykh</surname><given-names>V. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Береговых Валерий Васильевич, академик РАН, доктор технических наук, профессор, заместитель академика-секретаря отделения медицинских наук РАН, начальник отдела медицинских наук отделения медицинских наук РАН</p><p>Ленинский проспект, д. 14, г. Москва, 119991</p></bio><bio xml:lang="en"><p>Beregovykh Valery V., Academician of RAS, Dr. Sc. (Tech), Professor, Vice-Secretary of RAS Division for Medical Sciences, Head of department</p><p>14, Leninskiy Av., Moscow, 119991</p></bio><email xlink:type="simple">beregovykh@pran.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мешковский</surname><given-names>А. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Meshkovskiy</surname><given-names>A. P.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Мешковский Андрей Петрович, доцент кафедры промышленной фармации</p><p>ул. Трубецкая, д. 8, стр. 2, г. Москва, 119048</p></bio><bio xml:lang="en"><p>Meshkovskiy Andrei P., Associate Professor</p><p>8, Building 2, Trubetskaya Str., Moscow, 119048</p></bio><email xlink:type="simple">meshkvskijj@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Пятигорская</surname><given-names>Н. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Pyatigorskaya</surname><given-names>N. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Пятигорская Наталья Валерьевна, член-корреспондент РАН, доктор фармацевтических наук, профессор, заведующий кафедрой промышленной фармации</p><p>ул. Трубецкая, д. 8, стр. 2, г. Москва, 119048</p></bio><bio xml:lang="en"><p>Pyatigorskaya Natalia V., Corresponding Member of RAS, Dr. Sc. (Pharm), Professor, Head of Department</p><p> 8, Building 2, Trubetskaya Str., Moscow, 119048</p></bio><email xlink:type="simple">osipova-mma@list.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Федеральное государственное автономное образовательное учреждение высшего образование Первый Московский государственный медицинский университет имени И.М. Сеченова МЗ РФ (Сеченовский Университет)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of the Russian Federation (Sechenovskiy University)</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Федеральное государственное бюджетное учреждение «Российская академия наук»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Federal State Budget Organization “Russia Academy of Sciences”</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>07</day><month>10</month><year>2023</year></pub-date><volume>28</volume><issue>3</issue><fpage>108</fpage><lpage>136</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Аладышева Ж.И., Береговых В.В., Мешковский А.П., Пятигорская Н.В., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Аладышева Ж.И., Береговых В.В., Мешковский А.П., Пятигорская Н.В.</copyright-holder><copyright-holder xml:lang="en">Aladysheva Z.A., Beregovykh V.V., Meshkovskiy A.P., Pyatigorskaya N.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://federalizm.rea.ru/jour/article/view/805">https://federalizm.rea.ru/jour/article/view/805</self-uri><abstract><p>В текущем году в Российской Федерации принята Стратегия развития фармацевтической отрасли на период до 2030 г. В документе ставится задача обеспечения производства в стране лекарственных препаратов, конкурентоспособных на внутреннем и внешнем рынках, и «реализация экспортного потенциала фармацевтической отрасли». Особенностью фармацевтической отрасли является существенное влияние на экспорт различных аспектов государственного регулирования в сфере обращения лекарственных средств. Цель исследования – на основе анализа опыта зарубежных стран выявить важнейшие элементы государственного регулирования, способствующие формированию и развитию устойчивого экспорта лекарственных средств в условиях сложившейся олигопольной структуры экспортного сегмента мирового фармацевтического рынка. Учитывая объемность и разнообразие полученных данных, исследование было разделено на две части: анализ государственного регулирования сферы обращения лекарственных средств в странах – центрах экспорта лекарственных средств и в странах с быстро растущим фармацевтическим рынком. В настоящей статье рассмотрены особенности экспорта лекарственных средств и фармацевтического государственного регулирования в целом, приведен анализ стран-лидеров, выявлены основные факторы, ассоциирующиеся с успешными показателями экспорта, показаны текущие тенденции, предпринимаемые для удержания лидерства в этой области. Выявленные закономерности и регуляторные решения можно использовать для решения проблем региональных рынков на общенациональном уровне.</p></abstract><trans-abstract xml:lang="en"><p>This year, the Russian Federation adopted the Strategy for the Development of the Pharmaceutical Industry for the Period until 2030. The document sets the task of ensuring the production in the country of medicines that are competitive in the domestic and foreign markets, and “realizing the export potential of the pharmaceutical industry.” A feature of the pharmaceutical industry is the significant impact of various aspects of drug regulation on exports of medicines. The purpose of the study is to make an analysis of the experience of foreign countries and to identify the most important elements of drug regulation that contribute to the formation and development of sustainable export of medicines taking in the account the existing oligopoly structure of the export segment of the global pharmaceutical market. Considering the volume and diversity of the data obtained, the study was divided into two parts: an analysis of drug regulation in countries that are leaders in pharmaceutical export and in countries that are called pharma emerging markets. This article examines the features of export of pharmaceutical products and drug regulation, in general, provides an analysis of top exporters and demonstrates the main factors associated with successful pharmaceutical export, and shows current trends being taken by drug regulation authorities to maintain leadership in this area. The identified patterns and regulatory solutions can be used to solve the problems of regional markets at the national level.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>экспорт лекарственных средств</kwd><kwd>лекарственные средства</kwd><kwd>государственное регулирование лекарственных средств</kwd></kwd-group><kwd-group xml:lang="en"><kwd>export of medicines</kwd><kwd>medicines</kwd><kwd>state regulation of medicines</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Статья подготовлена по результатам исследования, выполненного при финансовой поддержке Российского научного фонда № 23-75-30012 «Снижение рисков полифармакотерапии с использованием искусственного интеллекта и анализа больших данных о лекарственных препаратах и их взаимодействиях» (https://rscf.ru/project/23-75-30012/).</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Arndt C., Buch C.M., Mattes A. Disentangling barriers to internationalization // Canadian Journal of Economics. 2012. Vol. 45. N 1. P. 41–63.</mixed-citation><mixed-citation xml:lang="en">Arndt C., Buch C.M., Mattes A. Disentangling barriers to internationalization, Canadian Journal of Economics, 2012, Vol. 45, No. 1, pp. 41–63.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Чугунова А.В., Клочко О.А. Взаимосвязь трансграничных слияний и поглощений и международной торговли: опыт фармацевтической отрасли России: 1 // Экономическая наука современной России. 2020. № 1. С. 81–94.</mixed-citation><mixed-citation xml:lang="en">Chugunova A.V., Klochko O.A. Vzaimosviaz’ transgranichnykh sliianii i pogloshchenii i mezhdunarodnoi torgovli: opyt farmatsevticheskoi otrasli Rossii: 1 [The Relationship Between Cross-Border Mergers and Acquisitions and International Trade: Experience of the Pharmaceutical Industry in Russia: 1], Ekonomicheskaia nauka sovremennoi Rossii [Economic Science of Modern Russia], 2020, No. 1, pp. 81–94. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Leonidou L.C. An Analysis of the Barriers Hindering Small Business Export Development // Journal of Small Business Management. 2004. Vol. 42. N 3. P. 279–302.</mixed-citation><mixed-citation xml:lang="en">Leonidou L.C. An Analysis of the Barriers Hindering Small Business Export Development, Journal of Small Business Management, 2004, Vol. 42, No. 3, pp. 279–302.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Hatzichronoglou T. Revision of the High-Technology Sector and Product Classification // OECD Science, Technology and Industry Working Papers. 1997. N 1997/02. URL: https://www.cepal.org/sites/default/files/events/files/septima-reunion-gtci-revision-high-technology-sector-product-classification-thomas-hatzi-chronoglou.pdf</mixed-citation><mixed-citation xml:lang="en">Hatzichronoglou T. Revision of the High-Technology Sector and Product Classification, OECD Science, Technology and Industry Working Papers, 1997, No. 1997/02. Available at: https://www.cepal.org/sites/default/files/events/files/septima-reunion-gtci-revision-high-technology-sector-product-classification-thomas-hatzichronoglou.pdf</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Garattini L., Padula A. Competition in pharmaceuticals: more productthan price-oriented? // The European Journal of Health Economics. 2018. Vol. 19. N 1. P. 1–4.</mixed-citation><mixed-citation xml:lang="en">Garattini L., Padula A. Competition in pharmaceuticals: more productthan price-oriented? The European Journal of Health Economics, 2018, Vol. 19, No. 1, pp. 1–4.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Mahajan V. Structural changes and trade competitiveness in the Indian pharmaceutical industry in product patent regime // International Journal of Pharmaceutical and Healthcare Marketing. 2019. Vol. 13. N 1. P. 21–39.</mixed-citation><mixed-citation xml:lang="en">Mahajan V. Structural changes and trade competitiveness in the Indian pharmaceutical industry in product patent regime, International Journal of Pharmaceutical and Healthcare Marketing, 2019, Vol. 13, No. 1, pp. 21–39.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Mohammadzadeh M., Aryanpour N. An Export-Marketing Model for Pharmaceutical Firms (the Case of Iran) // Iranian Journal of Pharmaceutical Research. 2013. Vol. 12. N 1. P. 249–255.</mixed-citation><mixed-citation xml:lang="en">Mohammadzadeh M., Aryanpour N. An Export-Marketing Model for Pharmaceutical Firms (the Case of Iran), Iranian Journal of Pharmaceutical Research, 2013, Vol. 12, No. 1, pp. 249–255.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Shabaninejad H., Yusefzadeh H., Mehralian G., Rahimi B. The Structure of the World Pharmaceutical Market: Prioritizing Iran’s Target Export Markets // Iranian Journal of Pharmaceutical Research. 2019. Vol. 18. N 1. P. 546–555.</mixed-citation><mixed-citation xml:lang="en">Shabaninejad H., Yusefzadeh H., Mehralian G., Rahimi B. The Structure of the World Pharmaceutical Market: Prioritizing Iran’s Target Export Markets, Iranian journal of pharmaceutical research, 2019, Vol. 18, No. 1, pp. 546–555.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Wiktorowicz M., Moscou K., Lexchin J. Transnational Pharmacogovernance: Emergent Patterns in the Jazz of Pharmaceutical Policy Convergence // Globalization and Health. 2018. Vol. 14. N 1. DOI:10.1186/s12992-018-0402-5</mixed-citation><mixed-citation xml:lang="en">Wiktorowicz M., Moscou K., Lexchin J. Transnational Pharmacogovernance: Emergent Patterns in the Jazz of Pharmaceutical Policy Convergence, Globalization and Health, 2018, Vol. 14, No. 1. DOI:10.1186/s12992-018-0402-5</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Shabaninejad H., Mehralian G., Rashidian A., Baratimarnani A., Rasekh H. R. Identifying and Prioritizing Industry-Level Competitiveness Factors: Evidence from Pharmaceutical Market // DARU Journal of Pharmaceutical Sciences. 2014. Vol. 22. N 1. DOI: 10.1186/2008-2231-22-35.</mixed-citation><mixed-citation xml:lang="en">Shabaninejad H., Mehralian G., Rashidian A., Baratimarnani A., Rasekh H. R. Identifying and Prioritizing Industry-Level Competitiveness Factors: Evidence from Pharmaceutical Market, DARU Journal of Pharmaceutical Sciences, 2014, Vol. 22, No. 1. DOI: 10.1186/2008-2231-22-35.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Shimura H., Masuda S., Kimura H. A Lesson From Japan: Research and Development Efficiency is a Key Element of Pharmaceutical Industry Consolidation Process // Drug Discoveries &amp; Therapeutics. 2014. Vol. 8. N 1. P. 57–63.</mixed-citation><mixed-citation xml:lang="en">Shimura H., Masuda S., Kimura H. A Lesson From Japan: Research and Development Efficiency is a Key Element of Pharmaceutical Industry Consolidation Process, Drug Discoveries &amp; Therapeutics, 2014, Vol. 8, No. 1, pp. 57–63.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Richman B.D., Mitchell W., E. Vidal, Schulman K. Pharmaceutical M&amp;A Activity: Effects on Prices, Innovation, and Competition // Loyola University Chicago Law Journal. 2017. Vol. 48. P. 788–819.</mixed-citation><mixed-citation xml:lang="en">Richman B.D., Mitchell W., E. Vidal, Schulman K. Pharmaceutical M&amp;A Activity: Effects on Prices, Innovation, and Competition, Loyola University Chicago Law Journal, 2017, Vol. 48, pp. 788–819.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Kyle M.K. The Alignment of Innovation Policy and Social Welfare: Evidence from Pharmaceuticals // Innovation Policy and the Economy. 2020. Vol. 20. P. 95–123.</mixed-citation><mixed-citation xml:lang="en">Kyle M.K. The Alignment of Innovation Policy and Social Welfare: Evidence from Pharmaceuticals, Innovation Policy and the Economy, 2020, Vol. 20, pp. 95–123.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Reis B., Pinto J.P.G. Center-Periphery Relationships of Pharmaceutical Value Chains: A Critical Analysis based on Goods and Knowledge Trade Flows // Review of Political Economy. 2022. Vol. 34. N 1. P. 124–145.</mixed-citation><mixed-citation xml:lang="en">Reis B., Pinto J.P.G. Center-Periphery Relationships of Pharmaceutical Value Chains: A Critical Analysis based on Goods and Knowledge Trade Flows, Review of Political Economy, 2022, Vol. 34, No. 1, pp. 124–145.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Mousavi S.Z., Rasekhi S., Golestani M., Imani A. Studying International Competitiveness In Pharmaceutical Sector In Selected Developed Countries // Asian Journal of Pharmaceutical and Clinical Research. 2018. Vol. 11. N 3. P. 451–460.</mixed-citation><mixed-citation xml:lang="en">Mousavi S.Z., Rasekhi S., Golestani M., Imani A. Studying International Competitiveness In Pharmaceutical Sector In Selected Developed Countries, Asian Journal of Pharmaceutical and Clinical Research, 2018, Vol. 11, No. 3, pp. 451–460.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Pauwels K., Simoens S., Casteels M., Huys I. Insights into European Drug Shortages: A Survey of Hospital Pharmacists // PLOS ONE. 2015. Vol. 10. N 3. URL: https://doi.org/10.1371/journal.pone.0119322</mixed-citation><mixed-citation xml:lang="en">Pauwels K., Simoens S., Casteels M., Huys I. Insights into European Drug Shortages: A Survey of Hospital Pharmacists, PLOS ONE, 2015, Vol. 10, No. 3. Available at: https://doi.org/10.1371/journal.pone.0119322</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Antalóczy K., Gáspár T., Sass M. The Specialties of the Pharmaceutical Value Chains in Hungary // Acta Oeconomica. 2019. Vol. 69. N S2. P. 41–72.</mixed-citation><mixed-citation xml:lang="en">Antalóczy K., Gáspár T., Sass M. The Specialties of the Pharmaceutical Value Chains in Hungary, Acta Oeconomica, 2019, Vol. 69, No. S2, pp. 41–72.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">De Backer K., Miroudot S. Mapping Global Value Chains // OECD Trade Policy Papers. 2013. N 159. URL: https://www.oecd-ilibrary.org/docserver/5k3v1trgnbr4-en. pdf?expires=1696252791&amp;id=id&amp;accname=guest&amp;checksum=FD0BB1AB718C3D120 A971F976536433D</mixed-citation><mixed-citation xml:lang="en">De Backer K., Miroudot S. Mapping global value chains, OECD Trade Policy Papers, 2013, No. 159. Available at: https://www.oecd-ilibrary.org/docserver/5k3v1trgnbr4-en.pdf?expires=1696252791&amp;id=id&amp;accname=guest&amp;checksum=FD0BB1AB718C3D120A971F976536433D</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Brennan L., Rakhmatullin R. Global Value Chains and Smart Specialisation Strategy. Joint Research Centre, Institute for Prospective Technological Studies, Publication Office. 2015. URL: https://op.europa.eu/en/publication-detail/-/publica-tion/c756898c-b379-11e5-8d3c-01aa75ed71a1/language-en</mixed-citation><mixed-citation xml:lang="en">Brennan L., Rakhmatullin R. Global Value Chains and Smart Specialisation Strategy. Joint Research Centre, Institute for Prospective Technological Studies, Publication Office, 2015. Available at: https://op.europa.eu/en/publication-detail/-/publication/c756898c-b379-11e5-8d3c-01aa75ed71a1/language-en</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Cezar R. France’s Pharmaceutical Industry in Global Value Chains // Quarterly Selection of Articles – Bulletin de la Banque de France. Banque de France. 2016. N 44. P. 52–63.</mixed-citation><mixed-citation xml:lang="en">Cezar R. France’s pharmaceutical industry in global value chains, Quarterly selection of articles – Bulletin de la Banque de France. Banque de France, 2016, No. 44, pp. 52–63.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Missoni E. Understanding the Impact of Global Trade Liberalization on Health Systems Pursuing Universal Health Coverage // Value in Health. 2013. Vol. 16. N 1. P. S14–S18.</mixed-citation><mixed-citation xml:lang="en">Missoni E. Understanding the Impact of Global Trade Liberalization on Health Systems Pursuing Universal Health Coverage, Value in Health, 2013, Vol. 16, No. 1, pp. S14–S18.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Pateriya S. et al. Regulatory Aspects of Pharmaceuticals’ Exports In Gulf Cooperation Council Countries // Journal of Young Pharmacists. 2011. Vol. 3. N 2. P. 155–162.</mixed-citation><mixed-citation xml:lang="en">Pateriya S. et al. Regulatory aspects of pharmaceuticals’ exports in gulf cooperation council countries, Journal of young pharmacists, 2011, Vol. 3, No. 2, pp. 155–162.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Lee K.S., Ming L. C., Lean Q. Y., Yee S. M., Patel R., Taha N. A., Kassab Y. W. Cross-border Collaboration to Improve Access to Medicine: Association of Southeast Asian Nations Perspective // Journal of Epidemiology and Global Health. 2019. Vol. 9. N 2. P. 93–97.</mixed-citation><mixed-citation xml:lang="en">Lee K.S., Ming L. C., Lean Q. Y., Yee S. M., Patel R., Taha N. A., Kassab Y. W. Cross-border Collaboration to Improve Access to Medicine: Association of Southeast Asian Nations Perspective, Journal of Epidemiology and Global Health, 2019, Vol. 9, No. 2, pp. 93–97.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Park J., Shin H., Kim J. et al. Analysis of Trends in Regulatory Science and Regulatory Science Experts Training Projects: US, Japan, Singapore, and Korea // Korean Journal of Clinical Pharmacy. Korean College of Clinical Pharmacy. 2021. Vol. 31. N 4. P. 257–267.</mixed-citation><mixed-citation xml:lang="en">Park J., Shin H., Kim J. et al. Analysis of Trends in Regulatory Science and Regulatory Science Experts Training Projects: US, Japan, Singapore, and Korea, Korean Journal of Clinical Pharmacy. Korean College of Clinical Pharmacy, 2021, Vol. 31, No. 4, pp. 257–267.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Shi J., Chen X., Hu H., Ung C.O.L. Application of implementation science framework to develop and adopt regulatory science in different national regulatory authorities // Frontiers in Public Health. 2023. Vol. 11. URL: https://www.frontiersin.org/articles/10.3389/fpubh.2023.1172557/full</mixed-citation><mixed-citation xml:lang="en">Shi J., Chen X., Hu H., Ung C.O.L. Application of implementation science framework to develop and adopt regulatory science in different national regulatory authorities, Frontiers in Public Health, 2023, Vol. 11. Available at: https://www.frontiersin.org/articles/10.3389/fpubh.2023.1172557/full</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Garattini S., Natsis Y., Banzi R. Pharmaceutical Strategy for Europe: Reflections on Public Health-Driven Drug Development, Regulation, and Policies // Frontiers in Pharmacology. 2021. Vol. 12. URL: https://www.frontiersin.org/articles/10.3389/fphar.2021.685604/full</mixed-citation><mixed-citation xml:lang="en">Garattini S., Natsis Y., Banzi R. Pharmaceutical Strategy for Europe: Reflections on Public Health-Driven Drug Development, Regulation, and Policies, Frontiers in Pharmacology, 2021, Vol. 12. Available at: https://www.frontiersin.org/articles/10.3389/fphar.2021.685604/full</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Saesen R., Machado M., Crifo B. et al. Involvement of the European Medicines Agency in Multi-Stakeholder Regulatory Science Research Projects: Experiences of Staff Members and Project Coordinators // Frontiers in Medicine. 2023. Vol. 10. URL: https://www.frontiersin.org/articles/10.3389/fmed.2023.1181702/full</mixed-citation><mixed-citation xml:lang="en">Saesen R., Machado M., Crifo B. et al. Involvement of the European Medicines Agency in Multi-Stakeholder Regulatory Science Research Projects: Experiences of Staff Members and Project Coordinators, Frontiers in Medicine, 2023, Vol. 10. Available at: https://www.frontiersin.org/articles/10.3389/fmed.2023.1181702/full</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Shibata S., Ozaki K., Suzuki T. Japanese Pharmaceutical Industry: Recent Perspectives and Areas for Further Research // Journal of Regulatory Science. 2020. Vol. 8. P. 1–13.</mixed-citation><mixed-citation xml:lang="en">Shibata S., Ozaki K., Suzuki T. Japanese Pharmaceutical Industry: Recent Perspectives and Areas for Further Research, Journal of Regulatory Science, 2020, Vol. 8, pp. 1–13.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Asahina Y., Tanaka A., Uyama Y., Kuramochi K., Maruyama H. The Roles of Regulatory Science Research in Drug Development at the Pharmaceuticals and Medical Devices Agency of Japan // Therapeutic Innovation &amp; Regulatory Science. 2013. Vol. 47, N 1. P. 19–22.</mixed-citation><mixed-citation xml:lang="en">Asahina Y., Tanaka A., Uyama Y., Kuramochi K., Maruyama H. The Roles of Regulatory Science Research in Drug Development at the Pharmaceuticals and Medical Devices Agency of Japan, Therapeutic Innovation &amp; Regulatory Science, 2013, Vol. 47, No. 1, pp. 19–22.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Okada K., Koike K., Sawa Y. Consideration of and expectations for the Pharmaceuticals, Medical Devices and Other Therapeutic Products Act in Japan // Regenerative Therapy. 2015. Vol. 1. P. 80–83.</mixed-citation><mixed-citation xml:lang="en">Okada K., Koike K., Sawa Y. Consideration of and expectations for the Pharmaceuticals, Medical Devices and Other Therapeutic Products Act in Japan, Regenerative Therapy, 2015, Vol. 1, pp. 80–83.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
